medigraphic.com
ISSN 2683-1678 (Impreso)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2018, Número 4

<< Anterior Siguiente >>

Rev Latin Infect Pediatr 2018; 31 (4)


Estado actual del sarampión Comportamiento en Latinoamérica

Herrera-Benavente IF, Mascareñas-de los Santos AH, Rodríguez-Barragán EE, Comas-García A, Ochoa-Pérez UR

Idioma: Español
Referencias bibliográficas: 68
Paginas: 140-148
Archivo PDF: 273.48 Kb.


RESUMEN

El sarampión es una enfermedad exantemática, febril, muy contagiosa que es ocasionada por un virus ARN del género Morbillivirus. Ha sido y es actualmente responsable de un gran número de muertes en el mundo, principalmente en niños menores de cinco años de aquellos países que no aplican la vacuna contra el sarampión. La mejor manera de prevenir el sarampión es mediante la vacunación. Es posible su erradicación mundial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Shanks GD, Waller M, Briem H, Gottfredsson M. Age-specific measles mortality during the late 19th-early 20th centuries. Epidemiol Infect. 2015; 143: 3434-3441.

  2. Patel MK, Gacic-Dobo M, Strebel PM, Dabbagh A, Mulders MN, Okwo-Bele JM et al. Progress toward regional measles elimination-worldwide, 2000-2015. MMWR Morb Mortal Wkly Rep. 2016; 65 (44): 1228-1233.

  3. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015; 385 (9966): 430-440.

  4. Meeting of the International Task Force for Disease Eradication, November 2015. Weekly Epidemiol Rec. 2016; 91: 61-71.

  5. Moss WJ, Strebel P. Biological feasibility of measles eradication. J Infect Dis. 2011; 204: S47-53.

  6. Adams MJ, Lefkowitz EJ, King AMQ, Harrach B, Harrison RL, Knowles NJ et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017; 162 (8): 2505-2538.

  7. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000; 406: 893-897.

  8. Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature. 2011; 480 (7378): 530-553.

  9. Tahara M, Ohno S, Sakai K, Ito Y, Fukuhara H, Komase K et al. The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope. J Virol. 2013; 87 (6): 3583-3586.

  10. Plattet P, Alves L, Herren M, Aguilar HC. Measles virus fusion protein: structure, function and inhibition. Viruses. 2016; 8: 112.

  11. Mulders MN, Truong AT, Muller CP. Monitoring of measles elimination using molecular epidemiology. Vaccine. 2001; 19: 2245-2249.

  12. Moss WJ, Scott S, Ndhlovu Z, Monze M, Cutts FT, Quinn TC et al. Suppression of human immunodeficiency virus type 1 viral load during acute measles. Pediatr Infect Dis J. 2009; 28 (1): 63-65.

  13. WHO. Measles virus nomenclature update: 2012. Wkly Epidemiol Rec. 2012; 87: 73-81.

  14. https://www.cdc.gov/measles/lab-tools/genetic-analysis.html. [Consulted 12 October of 2018].

  15. Perry RT, Murray JS, Gacic-Dobo M, Dabbagh A, Mulders MN, Strebel PM et al. Progress toward regional measles elimination-worldwide, 2000-2014. MMWR Morb Mortal Wkly Rep. 2015; 64 (44): 1246-1251.

  16. Beaty SM, Lee B. Constraints on the genetic and antigenic variability of measles virus. Viruses. 2016; 8: 109.

  17. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med. 1954; 86: 277-286.

  18. Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P et al. Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. Cell Reports. 2015; 11 (9): 1331-1338.

  19. Mulders MN, Rota PA, Icenogle JP, Brown KE, Takeda M, Rey GJ et al. Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65 (17): 438-442.

  20. http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/. [Consulted 12 October of 2018].

  21. Organización Panamericana de la Salud/Organización Mundial de la Salud. Actualización Epidemiológica: Sarampión. 21 de septiembre de 2018, Washington, D.C.: OPS/OMS; 2018.

  22. Remington PL, Hall WN, Davis IH, Herald A, Gunn RA. Airborne transmission of measles in a physician’s office. JAMA. 1985; 253: 1574-1577.

  23. Hope K, Boyd R, Conaty S, Maywood P. Measles transmission in health care waiting rooms: implications for public health response. Western Pac Surveill Response J. 2012; 3 (3): 33-38.

  24. Dietz K. The estimation of the basic reproduction number for infectious diseases. Stat Method Med Res. 1993; 2: 23-41.

  25. Anderson RMR. Infectious diseases of humans. Oxford: Oxford University Press, 1991.

  26. Fine PE, Clarkson JA. Measles in England and Wales-I: an analysis of factors underlying seasonal patterns. Int J Epidemiol. 1982; 11: 5-14.

  27. Ferrari MJ, Grais RF, Bharti N, Conlan AJ, Bjørnstad ON, Wolfson LJ et al. The dynamics of measles in sub-Saharan Africa. Nature. 2008; 451 (7179): 679-684.

  28. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977; 91: 715-718.

  29. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010; 340: 1626.

  30. Waaijenborg S, Hahné SJ, Mollema L, Smits GP, Berbers GA, van der Klis FR et al. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis. 2013; 208 (1): 10-16.

  31. Durrheim DN, Crowcroft NS, Strebel PM. Measles-the epidemiology of elimination. Vaccine. 2014; 32: 6880-6883.

  32. Sugerman DE, Barskey AE, Delea MG, Ortega-Sanchez IR, Bi D, Ralston KJ et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics. 2010; 125 (4): 747-755.

  33. Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association between vaccine refusal and vaccine-preventable diseases in the United States: A review of measles and pertussis. JAMA. 2016; 315: 1149-1158.

  34. Nakatsu Y, Takeda M, Ohno S, Shirogane Y, Iwasaki M, Yanagi Y. Measles virus circumvents the host interferon response by different actions of the C and V proteins. J Virol. 2008; 82: 8296-8306.

  35. Bellini WJ, Helfand RF. The challenges and strategies for laboratory diagnosis of measles in an international setting. J Infect Dis. 2003; 187: S283-290.

  36. Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev. 2014: 4: Cd010056.

  37. Good RA, Zak SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics. 1956; 18: 109-149.

  38. von Pirquet C. Das Verhalten der kutanen Tuberkulin-reaktion während der Masern. Dtsch Med Wochenschr. 1908; 34 (30): 1297-1300.

  39. Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev. 2010; 236: 176-189.

  40. Tamashiro VG, Perez HH, Griffin DE. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr Infect Dis J. 1987; 6: 451-454.

  41. Akramuzzaman SM, Cutts FT, Wheeler JG, Hossain MJ. Increased childhood morbidity after measles is short-term in urban Bangladesh. Am J Epidemiol. 2000; 151: 723-735.

  42. Sartwell PE. The incubation period and the dynamics of infectious disease. Am J Epidemiol. 1966; 83: 204-206.

  43. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009; 9: 291-300.

  44. Fitzgerald TL, Durrheim DN, Merritt TD, Birch C, Tran T. Measles with a possible 23 day incubation period. Commun Dis Intel Quart Report. 2012; 36: E277-80.

  45. Riddell MA, Moss WJ, Hauer D, Monze M, Griffin DE. Slow clearance of measles virus RNA after acute infection. J Clin Virol. 2007; 39: 312-317.

  46. Choe YJ, Hu JK, Song KM, Cho H, Yoon HS, Kim ST et al. Evaluation of an expanded case definition for vaccine-modified measles in a school outbreak in South Korea in 2010. Jpn J Infect Dis. 2012; 65 (5): 371-375.

  47. Morley D. Severe measles in the tropics. I. BMJ. 1969; 1: 297-300.

  48. Moss WJ, Cutts F, Griffin DE. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis. 1999; 29: 106-112.

  49. Hutchins SS, Papania MJ, Amler R, Maes EF, Grabowsky M, Bromberg K et al. Evaluation of the measles clinical case definition. J Infect Dis. 2004; 189 (Suppl. 1): S153-59.

  50. Stevens GA, Bennett JE, Hennocq Q, Lu Y, De-Regil LM, Rogers L et al. Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys. Lancet Glob Health. 2015; 3 (9): e528-536.

  51. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004; 189: S4-16.

  52. Enders JF, Mc CK, Mitus A, Cheatham WJ. Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash. N Engl J Med. 1959; 261: 875-881.

  53. Foster A, Sommer A. Childhood blindness from corneal ulceration in Africa: causes, prevention, and treatment. Bull World Health Organ. 1986; 64: 619-623.

  54. Ogbuanu IU, Zeko S, Chu SY, Muroua C, Gerber S, De Wee R et al. Maternal, fetal, and neonatal outcomes associated with measles during pregnancy: Namibia, 2009-2010. Clin Infect Dis. 2014; 58 (8): 1086-1092.

  55. Griffin DE. Measles virus and the nervous system. Handb Clin Neurol 2014; 123: 577-590.

  56. Hardie DR, Albertyn C, Heckmann JM, Smuts HE Molecular characterisation of virus in the brains of patients with measles inclusion body encephalitis (MIBE). Virol J. 2013; 10: 283.

  57. Wendorf KA, Winter K, Zipprich J, Schechter R, Hacker JK, Preas C et al. Subacute sclerosing panencephalitis: the devastating measles complication is more common than we think. Clin Infect Dis. 2017; 65 (2): 226-232. doi: 10.1093/cid/cix302.

  58. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007; 36: 1334-1348.

  59. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol. 2009; 38: 192-205.

  60. Maltezou HC, Wicker S. Measles in health-care settings. Am J Infect Cont. 2013; 41: 661-663.

  61. Helfand RF, Heath JL, Anderson LJ, Maes EF, Guris D, Bellini WJ. Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset. J Infect Dis. 1997; 175: 195-199.

  62. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine. 2008; 26: 6392-6397.

  63. WHO. Measles vaccines: WHO position paper-April 2017. Wkly Epidemiol Rec. 2017; 92: 205-227.

  64. Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst Rev. 2005; 4: Cd001479.

  65. Barnard DL. Inhibitors of measles virus. Antiv Chem Chemother. 2004; 15: 111-119.

  66. Kabra SK, Lodha R. Antibiotics for preventing complications in children with measles. Cochrane Database Syst Rev. 2013; 8: Cd001477.

  67. Moss WJ, Scott S. The immunological basis for immunization serie. Module 7: Measles-Update 2009. Geneva: World Health Organization, 2009.

  68. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA. 1998; 280: 527-532.




2020     |     www.medigraphic.com